Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 12/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 12/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20590908 | 0.81 | CYP4F2 (0.58) | CYP4F2CYP4A11SLC6A4MRGPRX4F10 | |
| SCHEMBL22968202 | 0.79 | CYP4F2 (0.56) | CYP4F2CYP4A11SLC6A4MRGPRX4F10 | |
| SCHEMBL22968327 | 0.79 | CYP4F2 (0.61) | CYP4F2CYP4A11 | |
| SCHEMBL2370266 | 0.77 | MAOB (0.63) | MAOB | |
| SCHEMBL19277509 | 0.77 | CYP4F2 (0.69) | CYP4F2CYP4A11 | |
| SCHEMBL19277513 | 0.77 | CYP4F2 (0.66) | CYP4F2CYP4A11 | |
| SCHEMBL1889801 | 0.77 | MAOB (0.67) | MRGPRX4MAOB | |
| SCHEMBL22968091 | 0.77 | CYP4F2 (0.67) | CYP4F2CYP4A11 | |
| SCHEMBL19277476 | 0.77 | CYP4F2 (1.00) | CYP4F2CYP4A11 | |
| SCHEMBL22968354 | 0.77 | CYP4F2 (0.70) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141927-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | 大正製薬株式会社 | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | CYP4F2 8/4885CYP4A11 13/4885SLC6A4 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.